Clinical Trials
13 trialsNCT01451853 2026-06-03
SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss
Sound Pharmaceuticals, Incorporated
Phase 2 Withdrawn
NCT03402880 2026-05-29
ALCMI-005: Pembrolizumab and Epacadostat in Treating Patients With Extensive Stage Small Cell Lung Cancer
City of Hope Medical Center
Phase 2 Withdrawn
NCT06682013 2026-05-29
Virtual Agent Feasibility in Oncology Patients (NTT Data)
Duke University
Phase NA Withdrawn
NCT07073183 2026-05-29
Safety and Tolerability of CVHNLC Plus Pembrolizumab in Patients With Squamous Non Small-Cell Lung Cancer (sqNSCLC)
CureVac
Phase 1 Withdrawn
NCT03804255 2026-05-06
Assessment of Current Biomarker Testing Practices for Common Solid Cancers in Precision Oncology in the Community Setting
Eastern Cooperative Oncology Group
Withdrawn
NCT06732258 2026-04-29
Low-dose Radiotherapy Combined With Concurrent Chemotherapy, Toripalimab and Tifcemalimab in the Treatment of ES-SCLC
Sichuan University
Phase 1 Withdrawn
NCT07328490 2026-04-28
Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Withdrawn
NCT02633514 2026-04-27
Adjuvant Treatment for Incomplete Resection Thymoma or Thymic Carcinoma
Fudan University
Phase 3 Withdrawn
NCT06572722 2026-04-27
Perioperative Immunotherapy for NSCLC (ECTOP-1030)
Fudan University
Phase 2 Withdrawn
NCT06836414 2026-04-13
Lung Cancer Screening CT for Firefighters
University of California, San Francisco
Phase NA Withdrawn
NCT06434103 2026-04-08
Clinical Study of SHR-A1921 Combined With Adebrelimab and SHR-8068 With or Without Carboplatin in the Treatment of Advanced NSCLC
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1/2 Withdrawn
NCT06713798 2026-03-23
INDIGO
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Withdrawn
NCT06654050 2026-03-17
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn